NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Abbott's hepatitis C virus genotyping test for marketing in the US, the company said today.

The Abbott RealTime HCV Genotype II, which Abbott is launching today, determines the specific type or strain of HCV present in the blood of an infected patient, allowing physicians to create a targeted diagnosis and treatment. The test differentiates genotypes 1, 1a, 1b, 2, 3, 4, and 5, FDA said separately.

The test runs on Abbott's m2000 platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."